centerforbiosimilars

Luke Halpern

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

April Breyer Menon, JD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Hillel P. Cohen, PhD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

James D. Chambers, PhD, MPharm, MSc

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Gary Fanjiang, MD, MBA, MS

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Free CE Activities

Navigating Outpatient Bispecific Antibody Administration in Lymphoma: Practical Solutions for Community Oncolo ...
centerforbiosimilars

Tyler Sandahl, PharmD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Peter Pitts

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Christina Corridon, MPH, MBA

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Alex Keeton

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

FDA Approves Semglee Insulin Glargine as First Interchangeable Biosimilar

After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
centerforbiosimilars

The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...